Pontifax Management 4 G.P. (2015) Ltd.'s Net Worth
$45.7 Million
Who is Pontifax Management 4 G.P. (2015) Ltd.?
Pontifax Management 4 G.P. (2015) Ltd. has an estimated net worth of $45.7 Million. This is based on reported shares across multiple companies, which include Eloxx Pharmaceuticals, Inc., Keros Therapeutics, Inc., and 89bio, Inc..
SEC CIK
Pontifax Management 4 G.P. (2015) Ltd.'s CIK is 0001726334
Past Insider Trading and Trends
2020 was Pontifax Management 4 G.P. (2015) Ltd.'s most active year for acquiring shares with 21 total transactions. Pontifax Management 4 G.P. (2015) Ltd.'s most active month to acquire stocks was the month of March. 2020 was Pontifax Management 4 G.P. (2015) Ltd.'s most active year for disposing of shares, totalling 11 transactions. Pontifax Management 4 G.P. (2015) Ltd.'s most active month to dispose stocks was the month of March. 2019 saw Pontifax Management 4 G.P. (2015) Ltd. paying a total of $5,800,000.00 for 1,374,671 shares, this is the most they've acquired in one year. In 2022 Pontifax Management 4 G.P. (2015) Ltd. cashed out on 14,352 shares for a total of $0.71, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
89bio, Inc. (ETNB) Snapshot price: $8.385
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 1.13M |
$16.00 |
—
| 1.13M |
Nov 11 - Nov 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Keros Therapeutics, Inc. (KROS) Snapshot price: $51.395
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -0.15% | -7.18K |
—
| -$0.71 | 4.63M |
Nov 29
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| +1.27% | 60K |
$50.00 | $3,000,000.00 | 4.79M |
Nov 17
| |||
Form 4
| +31.88% | 3.98M |
$16.00 | $6,999,984.00 | 16.48M |
Apr 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Eloxx Pharmaceuticals, Inc. (ELOX) Snapshot price: $0.82125
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +275.43% | 5.93M |
$1.35 | $7,999,998.75 | 8.08M |
May 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 20
| |||
Form 4
| +10.25% | 200K |
$9.00 | $1,800,000.00 | 2.15M |
Jun 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 29
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 4
| +21.85% | 350K |
$9.75 | $3,412,500.00 | 1.95M |
Apr 30
| |||
Form 4
| +0.40% | 12.6K |
$7.78 | $97,830.00 | 3.2M |
Mar 21 - Mar 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||